Progenitor IPO forecasts up to $31.2 mil. in proceeds for the functional genomics firm.
Executive Summary
PROGENITOR SEEKING TO RAISE $27.1 MIL. IN INITIAL PUBLIC OFFERING of approximately 2.5 mil. shares at an estimated offering price of $12 per share, a June 6 prospectus states. Progenitor, a functional genomics company, is a subsidiary of Interneuron. The IPO would include an over-allotment option of 375,000 shares for underwriters Vector Securities International, Tucker Anthony and Genesis Merchant Group, which could increase net proceeds by $4.1 mil. Procceeds should keep the company operating for "at least the next 18 months," the prospectus estimates.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth